In Silico Pharmacology

, 5:4 | Cite as

Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b

  • Ashwini Khanderao Jadhav
  • Sankunny Mohan Karuppayil
Original Research


DNA relaxation is an important step in DNA replication. DNA topoisomerases play a major role in DNA relaxation. Hence these enzymes are important targets for cancer drugs. DNA topoisomerase inhibitors bind to the transient enzyme–DNA complex and inhibit DNA replication. Various inhibitors of topoisomerase I and II are prescribed as drugs. Topoisomerase II is considered as an important target for the development of anticancer drugs. In this study we have demonstrated molecular docking of thirteen fluoroquinolines with human DNA topoisomerase II alpha (a) and beta (b). Fluoroquinolines are broad spectrum antibacterial antibiotics and it is highly effective against various bacterial infections. Some of the fluoroquinolines like moxifloxacin exert antifungal as well as anti-cancer activity. It forms complexes with topoisomerase II a and are responsible for stoppage DNA replication. Molecular docking studies showed that fluoroquinolines has shown formation of hydrogen bond and good binding affinity with human Topo2a and Topo2b. Hence FQs may inhibit the activity of enzyme topoisomerase by binding at its active site. Ofloxacin, sparafloxacin, ciprofloxacin and moxifloxacin are predicted to be the most potent inhibitors among the thirteen FQs docked. GLN773, ASN770, LYS723 and TRP931 amino acid residues of Topo2a are involved in binding with FQs while ASP479, SER480, ARG820, ARG503, LYS456 and GLN778 amino acid residues of Topo2b are involved in binding with FQs. Our in silico study suggests that fluoroquinolines could be repositioned as DNA topoisomerase II inhibitors hence can be used as anticancer drugs. In vitro and in vivo experiments need to be done to confirm their efficacy.


Human DNA topoisomerase II Fluoroquinolines Anticancer Molecular docking In silico Drug repositioning 


  1. Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53:1565–1574CrossRefPubMedPubMedCentralGoogle Scholar
  2. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JYN, Wang JC, Liu LF (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natal Acad Sci USA 104(26):11014–11019CrossRefGoogle Scholar
  3. Bertozzi D, Iurlaro R, Sordet O, Marinello J, Zaffaroni N, Capranico G (2011) Characterization of novel antisense HIF-1α transcripts in human cancers. Cell Cycle 10(18):3189–3197CrossRefPubMedGoogle Scholar
  4. Bertozzi D, Marinello J, Manzo SG, Fornari F, Gramantieri L, Capranico G (2014) The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther 13(1):239–248CrossRefPubMedGoogle Scholar
  5. Bromberg KD, Burgin AB, Osheroff N (2003a) Quinolone action against human topoisomerase II alpha: stimulation of enzyme mediated double-stranded DNA cleavage. Biochemistry 42:3393–3398CrossRefPubMedGoogle Scholar
  6. Bromberg KD, Burgin AB, Osheroff N (2003b) Quinolone action against human topoisomerase II alpha: stimulation of enzyme mediated double-stranded DNA cleavage. Biochemistry 42:3393–3398CrossRefPubMedGoogle Scholar
  7. Chan PF, Huang J, Bax BD, Gwynn MN (2013) Recent developments in inhibitors of bacterial type IIA topoisomerases. In: Gualerzi CO, Brandi L, Fabbretti A, Pon CL (eds) Antibiotics: targets, mechanisms and resistance. Wiley, Weinheim. doi:10.1002/9783527659685.ch11 CrossRefGoogle Scholar
  8. Chen SH, Chan NL, Hsieh TS (2013) New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem 82:139–170CrossRefPubMedGoogle Scholar
  9. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK (1989) Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci 86(23):9431–9435CrossRefPubMedPubMedCentralGoogle Scholar
  10. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Crooke ST (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem 262(34):16739–16747PubMedGoogle Scholar
  11. Drwal MN, Agama K, Pommier Y, Griffith R (2013) Development of purely structure-based pharmacophores for the topoisomerase I-DNA-ligand binding pocket. J Comput Aided Mol Des 27(12):1037–1049CrossRefPubMedGoogle Scholar
  12. Fabian I, Reuveni D, Levitov A, Halperin D, Priel E, Shalit I (2006) Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer 95(8):1038–1046CrossRefPubMedPubMedCentralGoogle Scholar
  13. Jadhav A, Bansode B, Phule D, Shelar A, Patil R, Gade W, Karuppayil SM (2017) The antibacterial agent, moxifloxacin inhibits virulence factors of Candida albicans through multitargeting. World J Microbiol Biotechnol 33(5):96CrossRefPubMedGoogle Scholar
  14. Kumar A, Bora U (2014) Molecular docking studies of curcumin natural derivatives with DNA topoisomerase I and II-DNA complexes. Interdiscip Sci Comput Life Sci 6(4):285–291CrossRefGoogle Scholar
  15. Marinello J, Chillemi G, Bueno S, Manzo SG, Capranico G (2013) Antisense transcripts and R-loops caused by DNA topoisomerase I inhibition by camptothecin at human active CpG island promoters. Cancer Res 73(8 Supplement). doi:10.1158/1538-7445.AM2013-637
  16. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19(14):1639–1662CrossRefGoogle Scholar
  17. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338–350CrossRefPubMedPubMedCentralGoogle Scholar
  18. Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8:82–95CrossRefPubMedPubMedCentralGoogle Scholar
  19. Robinson MJ, Martin BA, Gootz TD et al (1991) Effects of quinolone derivatives on eukaryotic topoisomerase-II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem 266:14585–14592PubMedGoogle Scholar
  20. Shen LL, Baranowski J, Pernet AG (1989) Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry 28:3879–3885CrossRefPubMedGoogle Scholar
  21. Tsutsui K, Tsutsui K, Sano K, Kikuchi A, Tokunaga A (2001) Involvement of DNA topoisomerase IIβ in neuronal differentiation. J Biol Chem 276(8):5769–5778CrossRefPubMedGoogle Scholar
  22. Wang S, Miller W, Milton J, Vicker N, Stewart A, Charlton P, Denny WA (2002) Structure–activity relationships for analogues of the phenazine-based dual topoisomerase I/II inhibitor XR11576. Bioorg Med Chem Lett 12(3):415–418CrossRefPubMedGoogle Scholar
  23. Yang X, Li W, Prescott ED, Burden SJ, Wang JC (2000) DNA topoisomerase IIβ and neural development. Science 287(5450):131–134CrossRefPubMedGoogle Scholar
  24. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639–1642CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Ashwini Khanderao Jadhav
    • 1
  • Sankunny Mohan Karuppayil
    • 1
  1. 1.School of Life Sciences (DST-FIST and UGC-SAP Sponsored)SRTM University (NAAC Accredited with ‘A’ Grade)NandedIndia

Personalised recommendations